Neflamapimod
Dementia with Lewy Bodies (DLB)
Key Facts
About CervoMed
CervoMed (formerly EIP Pharma) is a US-based biotech focused on age-related neurological disorders, operating on the premise that early-stage neurodegeneration is driven by reversible synaptic dysfunction caused by neuroinflammation. The company's lead asset, neflamapimod, has demonstrated positive Phase 2b data in Dementia with Lewy Bodies and has obtained FDA alignment for a Phase 3 trial. With an experienced leadership team including former Vertex and Biogen executives, CervoMed is advancing a targeted approach to treat DLB patients without Alzheimer's co-pathology, addressing a significant unmet need in the second most common progressive dementia.
View full company profileAbout CervoMed
CervoMed (formerly EIP Pharma) is a US-based biotech focused on age-related neurological disorders, operating on the premise that early-stage neurodegeneration is driven by reversible synaptic dysfunction caused by neuroinflammation. The company's lead asset, neflamapimod, has demonstrated positive Phase 2b data in Dementia with Lewy Bodies and has obtained FDA alignment for a Phase 3 trial. With an experienced leadership team including former Vertex and Biogen executives, CervoMed is advancing a targeted approach to treat DLB patients without Alzheimer's co-pathology, addressing a significant unmet need in the second most common progressive dementia.
View full company profileAbout CervoMed
CervoMed (formerly EIP Pharma) is a US-based biotech focused on age-related neurological disorders, operating on the premise that early-stage neurodegeneration is driven by reversible synaptic dysfunction caused by neuroinflammation. The company's lead asset, neflamapimod, has demonstrated positive Phase 2b data in Dementia with Lewy Bodies and has obtained FDA alignment for a Phase 3 trial. With an experienced leadership team including former Vertex and Biogen executives, CervoMed is advancing a targeted approach to treat DLB patients without Alzheimer's co-pathology, addressing a significant unmet need in the second most common progressive dementia.
View full company profile